Acuvue Abiliti 1-Day lenses show 3-year myopia control effect
Johnson & Johnson's Acuvue Abiliti 1-Day lenses showed significant reduction in myopia progression in children over 3 years, with lower axial length growth (0.21 mm vs. 0.53 mm) and refraction change (–0.24 D vs. –0.98 D) compared to controls. Visual acuity remained 20/20 or better. The lenses are not FDA-approved but are approved in Canada.
How this was made
The 30-second read
Why it matters
The data provides the first quantitative evidence of the lens's efficacy, potentially enhancing JNJ's eye‑care growth outlook.
Market read
Positive trial results could boost JNJ's stock and stimulate interest in myopia‑control products across the sector.
What to watch
Pricing strategy, insurance coverage, and competition from existing myopia‑control lenses could limit upside.
Background
Johnson & Johnson presented 3‑year myopia‑control results for its Acuvue Abiliti 1-Day lens at Academy 2026, highlighting reduced axial length growth and refraction change versus single‑vision controls.
Ticker impact
Johnson & Johnson's Acuvue Abiliti 1-Day lens showed significantly lower myopia progression in a 3‑year study, the first public disclosure of these trial results.
likely modest upside as investors price in a new, effective myopia‑control product.
First‑time release of efficacy data for a novel contact‑lens design; no competing data released yet.
Market effects
Eye‑care and vision‑correction segment may see increased interest in myopia‑control technologies.
North American ophthalmology market could benefit from a new FDA‑pending product.
Potential ripple effect on global contact‑lens manufacturers evaluating similar designs.
Counterpoint
If the lens fails to gain FDA approval or faces reimbursement hurdles, the positive data may not translate into sales.
Key entities
- CompanyJohnson & Johnson
Manufacturer of Acuvue Abiliti 1-Day contact lenses.
- ConferenceAcademy 2026
Venue where the study results were presented.
